Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer

被引:89
作者
Devalapally, Harikrishna
Duan, Zhenfeng
Seiden, Michael V.
Amiji, Mansoor M.
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA
关键词
ovarian cancer; drug resistance; paclitaxel; C-6-ceramide; biodegradable polymeric nanoparticles; poly(ethylene oxide)-modified poly(epsilon-caprolactone);
D O I
10.1002/ijc.22886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this study was to overcome drug resistance upon systemic administration of combination paclitaxel (PTX) and the apoptotic signaling molecule C-6-ceramide (CER) in biodegradable poly(ethylene oxide)-modified poly(epsilon-caprolactone (PEO-PCL) nanoparticles. Subcutaneous sensitive (wild-type) and multidrug resistant (MDR-1 positive) SKOV-3 human ovarian adenocarcinoma xenografts were established in female Nu/Nu mice. PTX and CER were administered intravenously either as a single agent or in combination in aqueous solution and in PEO-PCL nanoparticles to the tumor-bearing mice. There was significant (p < 0.05) tumor growth suppression in both wild-type SKOV-3 and multidrug resistant SKOV-3(TR) models upon single dose co-administration of PTX (20 mg/kg) and CER (100 mg/kg) in nanoparticle formulations as compared to the individual agents and administration in aqueous solutions. For instance, in SKOV-3 wild-type model, more than 4.3-fold increase (p < 0.05) in tumor growth delay and 3.6-fold (p < 0.05) increase in tumor volume doubling time (DT) were observed with the combination treatment in nanoparticles as compared to untreated animals. Similarly, 3-fold increase (p < 0.05) in tumor growth delay and tumor volume DT was observed in SKOV-3(TR) model. Body weight changes and blood cells counts were used as measures of safety and, except for an increase in platelet counts (p < 0.05) in PTX + CER treated animals, there was no difference between various treatment strategies. The results of this study show that combination of PTX and CER in biodegradable polymeric nanoparticles can serve as a very effective therapeutic strategy to overcome drug resistance in ovarian cancer. (C) 2007 Wiley-Liss, Inc.
引用
收藏
页码:1830 / 1838
页数:9
相关论文
共 56 条
[21]   Regulation of ceramide production and apoptosis [J].
Kolesnick, RN ;
Krönke, M .
ANNUAL REVIEW OF PHYSIOLOGY, 1998, 60 :643-665
[22]   Accumulation of glucosylceramides in multidrug-resistant cancer cells [J].
Lavie, Y ;
Cao, HT ;
Bursten, SL ;
Giuliano, AE ;
Cabot, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (32) :19530-19536
[23]   Biodegradable, elastic shape-memory polymers for potential biomedical applications [J].
Lendlein, A ;
Langer, R .
SCIENCE, 2002, 296 (5573) :1673-1676
[24]   Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-α-induced apoptosis [J].
Liu, YY ;
Han, TY ;
Giuliano, AE ;
Ichikawa, S ;
Hirabayashi, Y ;
Cabot, MC .
EXPERIMENTAL CELL RESEARCH, 1999, 252 (02) :464-470
[25]   Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells [J].
Liu, YY ;
Han, TY ;
Giuliano, AE ;
Cabot, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (02) :1140-1146
[26]  
Lucci A, 1999, INT J ONCOL, V15, P541
[27]  
Lucci A, 1999, CANCER-AM CANCER SOC, V86, P300, DOI 10.1002/(SICI)1097-0142(19990715)86:2<300::AID-CNCR14>3.0.CO
[28]  
2-H
[29]   Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review [J].
Maeda, H ;
Wu, J ;
Sawa, T ;
Matsumura, Y ;
Hori, K .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :271-284
[30]   CHARACTERIZATION OF A CERAMIDE-ACTIVATED PROTEIN-KINASE - STIMULATION BY TUMOR-NECROSIS-FACTOR-ALPHA [J].
MATHIAS, S ;
DRESSLER, KA ;
KOLESNICK, RN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10009-10013